ICER Publishes Final Evidence Report and Policy Recommendations on Therapies for Multiple Myeloma
The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of three new treatments targeting the B-cell maturation antigen (BCMA) for heavily pre-treated patients with triple class refractory multiple myeloma (TCRMM) who have cycled through numerous previous lines of therapy: idecabtagene vicleucel (“ide-cel,” Abecma®, Bristol-Myers Squibb and bluebird bio), a chimeric antigen receptor (CAR) T-cell therapy that the FDA approved in March 2021 to treat TCRMM patients after four or more prior lines of therapy; ciltacabtagene autoleucel (“cilta-cel,” Janssen and Legend Biotech), an investigational CAR T-cell therapy for which a rolling biologic license application (BLA) seeking approval for the treatment of adults with relapsed and refractory multiple myeloma was completed in the first quarter of 2021; belantamab mafodotin-blmf (“belantamab,” Blenrep™, GlaxoSmithKline), which the FDA approved in August 2020 to treat TCRMM patients after four or more prior lines of therapy.